课题基金 / 基金详情

Enhancing ovarian cancer immunogenicity by increasing antitumoral responses using engineered oncolytic vaccines

Enhancing ovarian cancer immunogenicity by increasing antitumoral responses using engineered oncolytic vaccines
使用工程溶瘤疫苗增强抗肿瘤反应,从而增强卵巢癌的免疫原性
批准号:
370624
负责人:
Vanderhyden Barbara C
金额:
$66.32万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2017
资助国家:
加拿大
项目状态:
已结题
起止时间:
2017-09-01 至 2022-09-01

项目摘要

项目成果

Vanderhyden Barbara C的其他基金

相似基金

相关文献

中文摘要
翻译
癌症免疫疗法是一种革命性的方法,基于刺激我们体内的免疫反应以杀死癌细胞的方法。称为细胞毒性T淋巴细胞(CTL)的免疫细胞特异性识别癌细胞以消除它们。然而,在这方面,
英文摘要
Cancer immunotherapy is a revolutionary approach based on methods that stimulate the immune responses in our body to kill the cancer cells. Immune cells called cytotoxic T lymphocytes (CTLs) specifically recognize cancer cells to eliminate them. However,
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Increasing anti-tumoral responses to ovarian cancer using engineered viruses
  • 批准号:
    468827
  • 项目类别:
    Operating Grants
  • 资助金额:
    $66.04万
  • 财政年份:
    2022
  • 负责人:
    Vanderhyden Barbara C
  • 依托单位:
Reducing ovarian cancer risk by regulating age-associated ovarian fibrosis
  • 批准号:
    419086
  • 项目类别:
    Operating Grants
  • 资助金额:
    $49.6万
  • 财政年份:
    2020
  • 负责人:
    Vanderhyden Barbara C
  • 依托单位:
2020 Canadian Conference on Ovarian Cancer Research: Intensity Innovation, Improve Impact
  • 批准号:
    404263
  • 项目类别:
    Miscellaneous Programs
  • 资助金额:
    $0.73万
  • 财政年份:
    2019
  • 负责人:
    Vanderhyden Barbara C
  • 依托单位:
Role of ovarian epithelial progenitor cells in ovulatory wound repair
  • 批准号:
    306430
  • 项目类别:
    Operating Grants
  • 资助金额:
    $43.74万
  • 财政年份:
    2014
  • 负责人:
    Vanderhyden Barbara C
  • 依托单位:
海外基金